辛伐他汀对认知正常成人脑脊液阿尔茨海默病生物标志物的影响
一项为期12个月的随机安慰剂对照试验,在45-64岁认知正常且未使用过他汀的成人中评估辛伐他汀对脑脊液AD生物标志物的影响。结果显示两组间Aβ42、总tau和p-tau181的变化均无显著差异,但辛伐他汀组基线LDL越高,p-tau181下降越多(交互作用p=0.003)。
要点
- 辛伐他汀40mg/d治疗12个月未显著改变认知正常成人脑脊液Aβ42、总tau或p-tau181水平。
- 辛伐他汀组基线LDL与p-tau181变化存在显著交互作用(p=0.003),基线LDL越高p-tau181下降越多。
- 性别、APOE ε4、基线HDL或甘油三酯对治疗组与生物标志物变化的关系无显著修饰作用(均p>0.18)。
核心结论
- 辛伐他汀对脑脊液p-tau181的降低作用可能受基线LDL胆固醇水平调节。
- 辛伐他汀对脑脊液磷酸化tau的潜在疾病修饰作用应在高胆固醇人群中进一步研究。
研究设计与样本
- 12个月随机、安慰剂对照临床试验,纳入45-64岁认知正常、未使用他汀且胆固醇正常或轻度升高的成人。
- 辛伐他汀滴定至40mg/d;基线及治疗12个月后采用INNO-BIA AlzBio3 assay测定脑脊液Aβ42、总tau和p-tau181。
- 采用协方差分析比较两组生物标志物自基线的变化,校正年龄、性别和APOE ε4状态。
主要发现
- 两组间脑脊液Aβ42、总tau和p-tau181自基线变化均无显著差异,p值分别为0.53、0.36和0.25。
- 性别、APOE ε4、基线HDL或甘油三酯对治疗组与任一生物标志物变化的关系均无显著修饰作用(均p>0.18)。
- 治疗组与基线LDL对p-tau181存在显著交互作用(p=0.003),辛伐他汀组基线LDL越高,脑脊液p-tau181自基线下降越多。
临床怎么用
- 认知正常成人短期使用辛伐他汀40mg/d未显示对脑脊液AD核心生物标志物的显著整体影响。
- 对高LDL胆固醇患者,辛伐他汀可能更显著降低脑脊液p-tau181,但需进一步研究验证。
局限性
- 研究人群为认知正常且胆固醇正常或轻度升高的成人,结果不能外推至其他人群。
- 研究期限为12个月,无法评估长期效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure. METHODS: Participants were 45-64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol. Forty-six participants completed the 1-year study per protocol (25 in the simvastatin and 21 in the placebo group). Simvastatin was titrated to 40 mg/d. CSF Aβ42, total tau, and p-tau181 were measured at baseline and after 12 months of treatment using the INNO-BIA AlzBio3 assay. We used analysis of covariance to assess differences in biomarker change from baseline between treatment groups, adjusting for age, sex, and APOE ε4 status. RESULTS: Changes from baseline did not differ significantly between treatment groups for any CSF biomarker, with p values of 0.53, 0.36, and 0.25 for CSF Aβ42, total tau, and p-tau181, respectively. There was no significant modifying effect of sex, APOE ε4, or baseline high-density lipoprotein or triglycerides on treatment group for any of the biomarkers (all p > 0.18). However, a significant interaction between treatment group and baseline low-density lipoprotein (LDL) was observed for p-tau181 (p = 0.003), where greater decreases from baseline in CSF p-tau181 concentrations were associated with higher baseline LDL level for the simvastatin group. CONCLUSIONS: Simvastatin-related reductions in CSF p-tau181 concentrations may be modulated by LDL cholesterol. The potential disease-modifying effects of simvastatin on CSF phospho-tau should be further investigated in persons with hypercholesterolemia.
引用
- Li G, Mayer CL, Morelli D, et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology. 2017. PMID: 28821686. doi:10.1212/WNL.0000000000004392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。